{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:49:06Z","timestamp":1760150946885,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH109-9R19"],"award-info":[{"award-number":["KMUH109-9R19"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 108-2314-B-037-034-MY2"],"award-info":[{"award-number":["MOST 108-2314-B-037-034-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: This study aimed to evaluate the cost-effectiveness of treating transplant-ineligible myeloma patients with either a bortezomib plus thalidomide plus dexamethasone (VTD) or a bortezomib plus melphalan plus prednisolone (VMP) treatment in Taiwan. Methods: Newly diagnosed, transplant-ineligible myeloma patients with VTD or VMP therapy were enrolled from two medical centers in southern Taiwan. Quality-adjusted life years (QALYs) were used as the measurement unit of the effectiveness evaluation, and the incremental cost-effectiveness ratio (ICER) was used for comparison between the two groups. A net monetary benefit approach and cost-effectiveness acceptability curve were also used for the cost-effectiveness assessment. A one-way sensitivity analysis was used to check the impact of different parameters. In total, 77 patients were enrolled in the study with 43 patients in the VTD group and 34 patients in the VMP group. Clinical presentations were similar without significant difference, except the VTD group had a higher survival rate (p = 0.029). Comparisons of the two groups over an eight-month time horizon revealed a significant lower mean of direct medical costs in the VTD group than in the VMP group (p &lt; 0.001), and a significantly higher average QALY was gained (p &lt; 0.001). Conclusions: The study demonstrated the greater clinical benefit and cost-effectiveness of VTD compared to VMP therapy in transplant-ineligible, newly diagnosed myeloma patients.<\/jats:p>","DOI":"10.3390\/jpm12020130","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T08:20:57Z","timestamp":1642580457000},"page":"130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7311-4979","authenticated-orcid":false,"given":"Jeng-Shiun","family":"Du","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chun","family":"Kuo","sequence":"additional","affiliation":[{"name":"Master of Science in Healthcare Administration, Kaohsiung Medical University, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-0190","authenticated-orcid":false,"given":"Hon-Yi","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chung","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0042","authenticated-orcid":false,"given":"Tzer-Ming","family":"Chuang","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Lun","family":"Ke","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1634-2219","authenticated-orcid":false,"given":"Tsung-Jang","family":"Yeh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ching","family":"Gau","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8232-0387","authenticated-orcid":false,"given":"Hui-Ching","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan"},{"name":"Faculty of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Feng","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Faculty of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Yien","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rutgers-Camden, Camden, NJ 08102, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Faculty of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan"},{"name":"Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-6022","authenticated-orcid":false,"given":"Chin-Mu","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Hua","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Faculty of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan"},{"name":"Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan"},{"name":"Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: Every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/17474086.2020.1756258","article-title":"Newly diagnosed multiple myeloma: Current treatment strategies, emerging therapeutic approaches and beyond","volume":"13","author":"Kocoglu","year":"2020","journal-title":"Expert. Rev. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11899-020-00570-9","article-title":"Supportive Care in Multiple Myeloma","volume":"15","author":"Guzdar","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15410","article-title":"The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: A systematic review and economic evaluation","volume":"15","author":"Picot","year":"2011","journal-title":"Health Technol. Assess."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1586\/era.12.42","article-title":"Novel anticancer agents for multiple myeloma: A review of the evidence for their therapeutic and economic value","volume":"12","author":"Gaultney","year":"2012","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12571","article-title":"A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model","volume":"96","author":"Blommestein","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/CEOR.S104195","article-title":"Cost-effectiveness of bortezomib for multiple myeloma: A systematic review","volume":"8","author":"Chen","year":"2016","journal-title":"Clin. Outcomes Res."},{"key":"ref_12","first-page":"831","article-title":"Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer\u2019s Perspective","volume":"23","author":"Chen","year":"2017","journal-title":"J. Manag. Care Spec. Pharm"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"612696","DOI":"10.3389\/fmed.2021.612696","article-title":"Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects","volume":"8","author":"Kaweme","year":"2021","journal-title":"Front. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/jcpt.12384","article-title":"Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: What is the reporting quality?","volume":"41","author":"Aguiar","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s40273-019-00828-y","article-title":"Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review","volume":"37","author":"Fu","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-1-54","article-title":"The Health Utilities Index (HUI): Concepts, measurement properties and applications","volume":"1","author":"Horsman","year":"2003","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2004.00346.x","article-title":"Health related quality of life in patients with multiple myeloma undergoing a double transplantation","volume":"74","author":"Buijt","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"ref_18","first-page":"1159","article-title":"A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II\/III multiple myeloma; a prospective randomised phase III study","volume":"40","author":"Segeren","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-0609.2008.01126.x","article-title":"Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma","volume":"81","author":"Ludwig","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-118-8-199304150-00009","article-title":"Measuring health-related quality of life","volume":"118","author":"Guyatt","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_21","first-page":"350","article-title":"Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: A retrospective analysis","volume":"55","author":"Slovacek","year":"2008","journal-title":"Neoplasma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1600-0609.2010.01526.x","article-title":"The cost-effectiveness of bortezomib in relapsed\/refractory multiple myeloma: Swedish perspective","volume":"85","author":"Hornberger","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1634\/theoncologist.2011-0380","article-title":"The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment","volume":"18","author":"Garrison","year":"2013","journal-title":"Oncologist"},{"key":"ref_24","first-page":"1001","article-title":"Cost-Effectiveness of Bortezomib plus Cyclophosphamide plus Dexamethasone Versus Bortezomib plus Thalidomide plus Dexamethasone Versus Lenalidomide plus Dexamethasone as Induction Therapy for Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma in Colombia","volume":"1","author":"Rua","year":"2016","journal-title":"J. Hematol. Mult. Myeloma."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2012-0484","article-title":"Efficient allocation of novel agents in multiple myeloma: A work in progress","volume":"18","author":"Gaultney","year":"2013","journal-title":"Oncologist"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.23641","article-title":"Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study","volume":"89","author":"Morabito","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_27","first-page":"1887","article-title":"GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/2\/130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:03:54Z","timestamp":1760133834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/2\/130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jpm12020130"],"URL":"https:\/\/doi.org\/10.3390\/jpm12020130","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2022,1,19]]}}}